IMUNON delivered a smaller net loss of $4.1 million in Q1 2025, supported by reduced R&D expenses and progress in its IMNN-001 Phase 3 trial. The company closed the quarter with $2.9 million in cash and expects to fund operations through late Q2 2025.

IMUNON reported a net loss for 2024 of $18.6 million, or $1.62 per share, compared with a net loss for 2023 of $19.5 million, or $2.16 per share. The company ended 2024 with $5.9 million in cash and cash equivalents.

IMUNON reported a net loss of $4.9 million, or $0.34 per share, for the third quarter of 2024. The company had $10.3 million in cash, investments and accrued interest receivable as of September 30, 2024. The company believes it has sufficient capital resources to fund its operations into the third quarter of 2025.

IMUNON reported a net loss of $4.8 million for the second quarter of 2024. The company announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in advanced ovarian cancer and plans to hold an End-of-Phase 2 meeting with the FDA to clarify the path to a Phase 3 pivotal study.

IMUNON reported a net loss of $4.9 million, or $0.52 per share, for the first quarter of 2024, compared to a net loss of $5.6 million, or $0.68 per share, for the first quarter of 2023. The company's operating expenses decreased by 12% to $5.0 million. They ended the quarter with $9.8 million in cash, investments and accrued interest receivable.

IMUNON reported a net loss of $19.5 million for 2023, a decrease in operating expenses by 17% compared to 2022, and ended the year with $15.7 million in cash, investments and accrued interest receivable.

IMUNON reported a net loss of $3.5 million for Q3 2023, a decrease from the $6.1 million loss in Q3 2022. The company highlighted progress in its clinical development programs including IMNN-001 and PlaCCine.

IMUNON reported a net loss of $5.6 million, or $0.61 per share, for the second quarter of 2023, compared to a net loss of $6.0 million, or $0.87 per share, for the second quarter of 2022. The company's cash, investments and accrued interest receivable totaled $24.1 million as of June 30, 2023.

IMUNON reported a net loss of $5.6 million, or $0.68 per share, for the first quarter of 2023. The company's cash, investments and restricted cash totaled $37.3 million as of March 31, 2023, which, combined with planned future sales of New Jersey NOLs, is expected to fund operations into 2025.

IMUNON reported a net loss for 2022 of $35.9 million, or $5.03 per share. The company ended the year with $38.9 million in cash, investments, accrued interest receivable and restricted cash, sufficient to fund operations into 2025.

IMUNON reported a net loss of $6.1 million, or $0.87 per share, for the third quarter of 2022, compared to a net loss of $5.4 million, or $0.94 per share, for the third quarter of 2021. The company's operating expenses were $6.3 million for the third quarter of 2022, an increase of $1.1 million from the comparable prior-year period. The company ended the quarter with $43.4 million in cash, investments, restricted cash and accrued interest receivable and believes it has sufficient capital resources to fund its operations into 2025.

Celsion Corporation reported a net loss of $6.0 million ($0.87 per share) for the second quarter of 2022, compared to a net loss of $5.4 million ($0.95 per share) in 2021. The company's operating expenses were $6.1 million, a 17% increase from $5.2 million in the same period last year. Celsion ended the quarter with $48.1 million in cash, investments, and accrued interest receivable, which they believe is sufficient to fund operations into 2025.

Celsion Corporation reported a net loss of $10.5 million, or $1.82 per share, for the first quarter of 2022. The company's operating expenses were $6.0 million, and research and development expenses were $3.1 million. Celsion had $47.3 million in cash, investments and restricted cash as of March 31, 2022, and believes it has sufficient capital resources to fund its operations into the second quarter of 2025.

Celsion Corporation reported a net loss of $20.8 million ($3.83 per share) in 2021, compared with a net loss of $21.5 million ($10.08 per share) in 2020. With $56.9 million in cash and cash equivalents, restricted cash, short-term investments and interest receivable at December 31, 2021, the Company has sufficient capital resources to fund its operations through the end of 2024.

Celsion Corporation reported a net loss of $5.4 million, or $0.06 per share, for the quarter ended September 30, 2021, compared to a net loss of $8.1 million, or $0.24 per share, for the same period in 2020. The company ended the quarter with $60.6 million in cash, investment securities, restricted cash and accrued interest receivable, which is expected to fund operations through the end of 2024.

Celsion Corporation announced its second quarter 2021 financial results, reporting a net loss of $5.4 million, or $0.06 per share. The company highlighted encouraging resection results from the Phase II OVATION 2 Study and the expansion of its Vaccine Advisory Board. Celsion ended the quarter with $64.5 million in cash and believes it has sufficient capital to fund operations through 2024.

Celsion reported a net loss of $5.7 million, or $0.09 per share, for the first quarter of 2021. The company focused on immuno-oncology and next-generation vaccines, extended its cash operating runway through 2024, and strengthened its balance sheet by raising over $58 million in gross proceeds.

Celsion reported a net loss of $21.5 million ($0.67 per share) in 2020, compared with a net loss of $16.8 million ($0.77 per share) in 2019. The company is focusing on DNA-based immunotherapies and next-generation vaccines, supported by a strong balance sheet.

Celsion Corporation reported a net loss of $8.1 million, or $0.24 per share, for the quarter ended September 30, 2020, compared to a net loss of $5.5 million, or $0.25 per share, for the same period in 2019. The company continues to follow patients for overall survival in the Phase III OPTIMA Study and initiated the Phase II OVATION 2 Study of GEN-1 in advanced ovarian cancer.

Celsion reported a net loss of $5.3 million for the second quarter of 2020. The company is continuing to follow patients in the Phase III OPTIMA study for overall survival and initiated a Phase II study of GEN-1 in advanced ovarian cancer.

Celsion Corporation reported a net loss of $5.1 million, or $0.20 per share, for the first quarter of 2020. The company continued to advance its clinical development programs with ThermoDox® and GEN-1 and maintained a strong balance sheet.

Celsion reported a net loss of $16.9 million for the year ended December 31, 2019, with operating expenses at $21.1 million. The company highlighted progress with ThermoDox® and GEN-1 development programs and a strong balance sheet, anticipating key milestones in 2020.